ITB-MED AB
559017-9429ActiveDeveloping novel antibody therapy to eliminate post-transplant immunosuppression needs.
Biotechnology Companyitb-med.com
Yleiskatsaus
- 10–19
- Työntekijät
- 50–100milj SEK
- Liikevaihto
- 2015
- Perustettu
Kuvaus
ITB-MED is a specialized biotechnology company focused on transforming organ transplantation outcomes. The organization is developing TCD601 (siplizumab), a proprietary antagonistic CD2-directed monoclonal antibody. This novel therapy aims to achieve transplantation tolerance, potentially freeing pa...
Tunnisteet
B2BHealthTechPharmaceuticals
Avainsanat
AutoimmunityBiotechnology